Supplementary Material

# Supplementary Data

## Supplementary Figures

**Figure S1.** Selection process from the ARON-1 dataset.



**Figure S2.** 6-months and 12-month landmark analyses for Overall Survival and Progression-Free Survival in mRCC patients treated with first-line cabozantinib plus nivolumab. **(A)** 6-month landmark overall survival, **(B)** 12-month landmark overall survival, **(C)** 6-month landmark progression-free survival, and **(D)** 12-month landmark progression-free survival.

****

**(B)**

**(C)**

**(A)**

**(D)**

****

**Supplementary Figure 1.** The figure legends are required to have the same font as the main text, 12 point normal Times New Roman, single spaced. Please use a single paragraph for each legend and prepare the figures keeping in mind the PDF layout.